achieving LDL-C goals remains suboptimal, particularly in high-risk and very high-risk patients. The landscape of lipid lowering therapy has significantly evolved, with new consensus statements, newer agents, and important evidence
Pan-Asian studies have shown that a high proportion of high-risk and very high-risk patients on lipid-lowering therapy (LLT) are not achieving LDL-C goals [6]. Real-world studies of LLT management and LDL-C goals in the Asia–Pacific region found most patients (≥ 85%) to be treate...
Synopsis: A consensus conference report issued by American Diabetes Association and the American College of Cardiology Foundation (ADA/ACCF) recommends LDL cholesterol (LDL-C), non-HDL cholesterol (non-HDL-C), and apolipoprotein B (apoB) treatment goals for patients with cardiometabolic risk. ...
[1,2]. The reduction in CVD risk observed with lipid-lowering therapy has been shown to be proportional to the absolute reduction in LDL-C [1,2]. All currently available guidelines therefore recommend the use of lipid-lowering therapy to reduce LDL-C to specific treatment goals in people ...
2017 ADA指南提出了ACS患者更低的LDL-C目标值50 mg/dl,2017美国临床内分泌医师学会(AACE)和美国内分泌学会(ACE)最新2型糖尿病综合管理共识声明新增了超高危(有ASCVD事件病史、或3期或4期慢性肾脏病的2型糖尿病患者)患者的危险分层,并提出相应的LDL-C目标值<55 mg/dl。需要指出的是做出该推荐也正是基于...
Blood pressure of 79.5% of patients met the ADA recommendations by the end of the year 2014, reaching 86.6% in 2017. Moreover, 84.5% and 93.8% could reach the LDL-C goal in 2014 and 2017, respectively. The proportion for the patients meeting all three ABC goals were 23.2% and 42.1% ...